Company intelligence / Profile preview

Chongqing Bochuang Pharmaceuticals

Chongqing, Chongqing, China

Ownership: Private
Development stage: Other

Overview

Ongericimab, a recombinant humanized anti-PCSK9 monoclonal antibody, has demonstrated robust LDL-C lowering (>60%) in large phase 3 trials and is approved in China for hypercholesterolemia and mixed dyslipidemia (including in statin-intolerant patients); commercialization rights in China have been exclusively licensed to Bochuang Pharmaceuticals by Junshi Biosciences.

Therapeutic areas: Cardiovascular
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Junshi Biosciences (exclusive license for ongericimab commercialization/rights in China)

Beyond the preview

Go deeper on Chongqing Bochuang Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Bochuang Pharmaceuticals.

Explore the full profile